Emery Pharma Builds New Biologics Analytical Division

Emery Pharma has expanded its lab. The extension of its new laboratory is streamlined to support research and development of large molecule drugs including, biologics, antibody-drug conjugates, biosimilars and others.

Emery Pharma's expertise continues to grow with the addition of Dr. Rodney Bannwart. Dr. Bannwart has considerable experience in pharmaceutical analysis, holding advanced scientific positions at Pfizer, Abbott, Novartis, and Alcon. "Rodney is a pharmaceutical veteran and previously jumpstarted Alcon's Biologics Mass Spectrometry capabilities with great success. We are excited for him to lead the new Large Molecule Analytical Division at Emery Pharma," said Dr. Neel Bose, CSO.

In addition to the High-Resolution Orbitrap Mass Spectrometer, the newly established laboratory features brand-new instruments for Ultrahigh Performance Liquid Chromatography (UPLC) equipped with a Diode Array Detector (DAD), Charged Aerosol Detector (CAD), and Refractive Index (RI) detector, Gas Chromatography Mass Spectrometry (GC-MS), and Semi-Preparative High-Performance Liquid Chromatography (HPLC). With the addition of these new top-of-the-line instruments, Emery Pharma continues to offer quality, flexibility, and innovative concepts to help accelerate the drug development process.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!

  • <<
  • >>

Join the Discussion